Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 2, 2011, Pages

  Sissung, Tristan M ^a   Danesi, Romano ^b   Kirkland, C Tyler ^a   Baum, Caitlin E ^a   Ockers, Sandra B ^a   Stein, Erica V ^c   Venzon, David ^a   Price, Douglas K ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PISA   (Italy)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; DOCETAXEL; ESTRAMUSTINE; ESTROGEN RECEPTOR ALPHA; KETOCONAZOLE; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME POLYMORPHISM; ESTROGEN SYNTHESIS; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; GENOTYPE; HUMANS; MALE; ORCHIECTOMY; POLYMORPHISM, GENETIC; PROGNOSIS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 79951695882     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2070     Document Type: Article

References (20)

1. Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R 2010 Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Cancer 10:511
2. Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A 2008 Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther 7:19-26
3. Sissung TM, Price DK, Sparreboom A, Figg WD 2006 Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 4:135-150
4. Williams GP 2010 The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease. Eur J Cancer Prev 19:256-271.
5. Ellem SJ, Risbridger GP 2007 Treating prostate cancer: a rationale for targeting local oestrogens. Nat Rev Cancer 7:621-627 (Pubitemid 47108185)
6. Travis RC, Schumacher F, Hirschhorn JN, Kraft P, Allen NE, Albanes D, Berglund G, Berndt SI, Boeing H, Bueno-de-Mesquita HB, Calle EE, Chanock S, Dunning AM, Hayes R, Feigelson HS, Gaziano JM, Giovannucci E, Haiman CA, Henderson BE, Kaaks R, Kolonel LN, Ma J, Rodriguez L, Riboli E, Stampfer M, Stram DO, Thun MJ, Tjønneland A, Trichopoulos D, Vineis P, Virtamo J, Le Marchand L, Hunter DJ 2009 CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 18:2734-2744
7. Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN 2007 Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 16:969-978 (Pubitemid 46910099)
8. Nicolaiew N, Cancel-Tassin G, Azzouzi AR, Grand BL, Mangin P, Cormier L, Fournier G, Giordanella JP, Pouchard M, Escary JL, Valeri A, Cussenot O 2009 Association between estrogen and androgen receptor genes and prostate cancer risk. Eur J Endocrinol 160:101-106
9. Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W 2007 Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int 99:1047-1055 (Pubitemid 46587914)
10. Figg WD, Liu M, Acharya MR, Gulley JL, Arlen PM, Lewis HL, Parnes CC, Jones E, Dahut W 2003 A phase I trial of high dose ketoconazole plus weekly docetaxel in metastatic androgen independent prostate cacner. Proc Am Soc Clin Oncol 22:1731 (Abstract)
11. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD 2004 Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22: 2532-2539 (Pubitemid 41103740)
12. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Krüger EA, Gubish E, Pluda JM, Reed E 2001 A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7:1888-1893 (Pubitemid 32994822)
13. Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL, Thompson IM, Leach RJ 2009 Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 18:1869-1880
14. Low YL, Taylor JI, Grace PB, Mulligan AA, Welch AA, Scollen S, Dunning AM, Luben RN, Khaw KT, Day NE, Wareham NJ, Bingham SA 2006 Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr Cancer 56:31-39 (Pubitemid 46173412)
15. Jankowska EA, Rogucka E, Medraoe M, Welon Z 2000 Relationships between age-related changes of sex steroids, obesity and body fat distribution among healthy Polish males. Med Sci Monit 6:1159-1164 (Pubitemid 32009577)
16. Martinez VG, O'Connor R, Liang Y, Clynes M 2008 CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance. Br J Cancer 98:564-570 (Pubitemid 351214524)
17. Haldar S, Basu A, Croce CM 1997 Bcl2 is the guardian of microtubule integrity. Cancer Res 57:229-233 (Pubitemid 27038278)
18. Friedman AE 2007 Can a single model explain both breast cancer and prostate cancer? Theor Biol Med Model 4:28
19. Kandouz M, Siromachkova M, Jacob D, Chretien Marquet B, Therwath A, Gompel A 1996 Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells. Int J Cancer 68:120-125 (Pubitemid 26354589)
20. Henderson BE, Feigelson HS 2000 Hormonal carcinogenesis. Carcinogenesis 21:427-433 (Pubitemid 30137927)